

*Correlation of Hepatitis C Viral Load With
The Outcome of Stem Cell Therapy In Post
Hepatitis C Cirrhotic Patients*

*Thesis submitted for partial fulfillment of the
Master Degree in Tropical Medicine*

Submitted by

Ghada Ahmed Saad
M.B.,B.Ch.

Under supervision of

Prof. Dr. Hosny Salama
Professor of Tropical Medicine
Faculty of Medicine
Cairo University

Prof. Dr. Hanan Abdel-Haleem
Professor of Tropical Medicine
Faculty of Medicine
Cairo University

Prof. Dr. Abdel-Rahman Zekri
Professor of Molecular Virology and Immunology
National Cancer Institute
Cairo University

**Faculty of Medicine
Cairo University**

2010

ABSTRACT

BACKGROUND The worldwide shortage of donor livers has prompted the search for alternative cell therapies for patients suffering from end-stage liver disease, including the transplantation of stem/progenitor cells. As outcome of stem cell therapy in post HCV end stage liver cirrhosis is variable and patients receiving stem cell therapy for non viral end stage liver cirrhosis had better outcome. This study was designed to determine the relation between HCV viral load and the outcome of stem cell therapy in patients with post HCV liver cirrhosis.

METHODS We report thirty post HCV liver cirrhosis (LC) patients that underwent bone marrow stem cell (BMSC) transplantation in the portal vein. Subjects were patients with post-HCV LC with abnormal liver functions. G-CSF was administered to suitable patients to increase their haematopoietic stem cells (HSCs) from the bone marrow. HSCs were isolated&seperated, CD34+ cells were isolated and injected in the patients. After stem cell therapy, liver function&HCV viral load were monitored for 6 months.

RESULTS There was significant improvement as regards PC and non-significant improvement as regards serum albumin and bilirubin levels . There was improvement in the hepatic functional reserve as assessed by the Child-Pugh score. There was significant improvement as regards performance score (PS). By the end of the study, 63.6% showed improvement and none of the patients showed deterioration of the degree of ascites. The improvement was independent on HCV viral load.Safety of the procedure was evidenced by the low incidence of complications encountered. 7 patients (23.3%) suffered attacks of haematemesis .

CONCLUSIONS HSCs therapy may be considered a novel treatment for patients with decompensated LC.

Key words: Hematopoietic stem cells, bone marrow stem cell transplantation, cell therapy.

ACKNOWLEDGEMENT

First of all, thanks to **GOD** for his grace and mercy, and for giving me the effort to complete this work.

It was an honor to work under the supervision of eminent professors, who I appreciate their whole-hearted support. To them, I owe more than I can record.

I was fortunate enough to carry out this work under the supervision of **Prof. Dr. Hosny Salama**, Professor of Tropical Medicine, Cairo University. His care, perfectionism and invaluable experience were of much guidance to me. He sincerely supported me throughout this work and offered any possible help to overcome every difficulty I faced. Thanks for always being a father before being a teacher.

Words will never be able to express my deepest gratitude and appreciation to **Prof. Dr. Hanan Abdel-Haleem**, Professor of Tropical Medicine, Cairo University for her strict supervision and revision of this work. She gave me much of her time, experience and support. Her valuable comments, efforts and collaboration were the causes to complete this work properly.

I would like to express my gratitude and thanks to **Prof. Dr. Abdel-Rahman Zekri**, Professor of Immunology and Virology, National Cancer Institute for his technical effort and guidance during all the steps done in the stem cell laboratory through this work.

Words will never be able to express my deepest gratitude and appreciation to **Dr. Rasha Ahmed**, lecturer of Tropical Medicine, Cairo University for her strict supervision and revision of this work. She gave me much of her time, experience and support. Her valuable comments, efforts and collaboration were the causes to complete this work properly.

I would like to thank **Dr. Dalia Ibrahim**, Lecturer of Community Medicine, Cairo University who did the statistical analysis of this study with much patience, faithfulness and devotion.

Last, but certainly not least, I owe to the patients included in this study, the whole of it. May God alleviate their sufferings and may all our efforts be just for their own benefit.

Table of contents

List of tables	i
List of figures.....	iii
List of abbreviations	v
 Introduction	 1
Aim of the work.....	5
Review of literature	6
Chapter One: Hepatitis C virus	
EPIDEMIOLOGY OF HEPATITIS C VIRUS.....	6
NATURAL HISTORY OF HEPATITIS C VIRUS.....	7
IMMUNE RESPONSE TO HEPATITIS C VIRUS.....	8
PATHOGENESIS OF POST HEPATITIC C FIBROSIS.....	9
• Factors affecting progression of post-hepatitic C fibrosis	10
• Correlation between serum titers of hepatitis C virus and severity of liver disease	12
• Reversibility of cirrhosis	13
COMPLICATIONS OF POST HEPATITIC C CIRRHOSIS,THEIR	13
PREVENTION&TREATMENT.....	
PROGNOSIS OF POST HEPATITIC C CIRRHOSIS.....	15
TREATMENT OF POST- HEPATITIC C CIRRHOSIS	16
• Liver transplantation	16
• Hepatocellular transplantation	19
Chapter Two: Hepatic Stem Cells	
STEM CELLS NOMENCLATURE	22
CLASSIFICATION OF STEM CELLS.....	22
SOURCES OF HEPATIC STEM CELL	24
• Mature Hepatocytes... ..	24
• Intrahepatic stem cells	24
• Extrahepatic stem cells	24
• Characteristic of an ideal hepatic stem cell.....	26
MATURE HEPATOCYTES.....	30
OVAL CELL	31
SMALL HEPATOCYTE LIKE PROGENIOTOR CELL.....	34
EMBRYONIC STEM CELL.....	35

BONE MARROW STEM CELL	36
MESENCHYMAI STEM CLL.....	38
HAEMATOPIOTIC STEM CELL	39
ETHICS IN STEM CELL RESEACH AND THERAPY.....	40
Chapter Three: BONE MARROW STEM CELLS THERAPY IN LIVER DISEASE	
WHICH BONE MARROW STEM CELLS POPULATE LIVER	44
THE BONE MARROW CONTRIBUTES SIGNIFICANTLY TO HEPATIC NON-PARENCHYMAL CELL POPULATION	46
FIBROGENIC CELLS IN THE LIVER CAN ORIGENATE FROM THE BONE MARROW	48
REGULATION OF BONE MARROW STEM CELLS HOMING TO THE LIVER	51
• Release of HSC from the bone marrow	51
• Hepatic recruitment of HSCs in liver injury	54
SITES OF TRANSPLANTED CELL.....	57
MECHANISM OF ENGRAFTMENT OF TRANSPLANTED CELLS	60
MECHANISM OF CONVERSION OF BONE MARROW STEM CELLS TO HEPATOCYTES.....	62
CLINICAL TRIALS OF BM TREATMENT IN LIVER DISEASE.....	66
EGYPTIAN TRIALS OF STEM CELL TRANSPLANTATION IN LIVER DISEASES.....	70
Chapter Four:	
FACTORS AFFECTING SERUM CONCENTRATION OF HEPATITIS C VIRUS.....	72
CORRELATION OF SERUM HCV TITRE WITH THE SEVERITY OF LIVER DISEASE	73
HEPATITIS C VIRAL LOAD AND TREATMENT OUTCOME.....	75
Predictive factors for sustained response to interferon treatment in chronic hepatitis c patients.....	75
• HCV RNA kinetics before and during interferon therapy.....	76
• HCV RNA kinetics during and post liver transplantation.....	77
• Recurrent hepatitis C after liver transplantation.....	77
RESPONSE TO STEM CELL THERAPY.....	79
Patients and Methods.....	80
Results.....	86
Discussion	135
Summary and Conclusions.....	146
Recommendations.....	150
References.....	151

List of tables

	Table	Page
Table (1)	Host and Viral Factors Affecting Fibrosis Progression in Chronic HCV Infection	11
Table (2)	Complications of post-Hepatitis C cirrhosis, their prevention & treatment	13
Table (3)	Child Pugh Turcotte (CPT) classification	15
Table (4)	Indications and contraindications for liver transplant	17
Table (5)	Demographic features of patients in the studied group	86
Table (6)	Clinical features of patients in studied group	87
Table (7)	Results of the laboratory investigations of studied group	88
Table (8)	Ultrasonographic features of the studied patients	89
Table (9)	Child-Pugh score of the studied patients at the start of the study	89
Table(10)	Change in HCV viral titre in the total studied population	90
Table(11)	HCV viral titre dynamics after 1,2,3 months and six months	91
Table(12)	Change in serum bilirubin in the total studied population	93
Table(13)	Response rate of bilirubin after 1,2,3 months and six months	94
Table(14)	Correlation of changes in HCV titre with changes in serum bilirubin in 1,2,3&6 months	95
Table(15)	Change in serum albumin in the total studied population	97
Table(16)	Albumin response rate after 1,2,3 months and six months	98
Table(17)	Correlation of changes in HCV titre with changes in serum albumin in 1,2,3&6 months	99
Table(18)	Change in PC in the total studied population	100
Table(19)	PC response rate after 1,2,3 months and six months	101
Table(20)	Correlation of changes in HCV titre with changes in PC in 1,2,3&6 months	102
Table(21)	Change in AST in the total studied population	103
Table(22)	AST response rate after 1,2,3 months and six months	104
Table(23)	Correlation of changes in HCV titre with changes in AST in 1,2,3&6 months	105
Table(24)	Change in ALT in the total studied population	108
Table(25)	ALT response rate after 1,2,3 months and six months	109
Table(26)	Correlation of changes in HCV titre with changes in ALT in 1,2,3&6 months	110
Table(27)	Progress of Child-Pugh score in the studied patients after 1, 2, 3, and 6 months of transplant	113
Table(28)	Child grade response rate after 1,2,3 months and six months	114

Table(29)	Association of changes in HCV titre with improvement child score	116
Table(30)	Progress of performance score in the studied patients before transplant, after 1, 2, 3 and 6 months	118
Table(31)	PS response rate after 1,2, 3 and 6 months	119
Table(32)	Association of changes in HCV titre with improvement in performance score	120
Table(33)	Progress of the degree of ascites in the studied population	122
Table(34)	Response rate in the degree of ascites after 1, 2, 3 & 6 months	123
Table(35)	Association of changes in HCV titre with improvement in degree of ascites	125
Table(36)	Cross table showing progress of hepatic coma after 1,2,3&6 months	126
Table(37)	Changes in the occurring of hepatic encephalopathy after 1, 2, 3 & 6 months	127
Table(38)	Association of changes in HCV titre with improvement in degree of encephalopathy	129
Table(39)	Cross table showing progress of haematemesis after 1,2,3&6 months	130
Table(40)	Change in the occurring of haematemesis after 1, 2, 3 & 6 months	131
Table(41)	Association of changes in HCV titre with improvement in haematemesis	132

List of figures

No.	Figure	Page
Fig. (1)	Scheme of liver stem cells. Liver stem cells	27
Fig. (2)	Multistep model of liver regeneration	28
Fig. (3)	Partial hepatectomy (PH) in a rat	31
Fig. (4)	BM stem cell population	44
Fig. (5)	Incorporation of BM-derived EPCs into the sinusoidal endothelium	48
Fig. (6)	Stem cell trafficking in liver injury	56
Fig. (7)	Potential uses of bone marrow-derived stem cells to treat liver disease and possible routes of inoculation	59
Fig. (8)	Distinguishing differentiation from fusion by cytogenetic analysis based on identifying sex chromosomes	63
Fig. (9)	Models of differentiation of HSCs into hepatocytes	64
Fig. (10)	Change in HCV viral titre in the total studied population	91
Fig. (11)	HCV viral titre dynamics after 1,2,3&6 months	92
Fig. (12)	Change in serum bilirubin in the total studied population	93
Fig. (13)	Response rate of bilirubin after 1,2,3 months and six months	94
Fig. (14)	Correlation of changes in HCV titre with changes in serum bilirubin in 3rd month	96
Fig. (15)	Change in serum albumin in the total studied population	97
Fig. (16)	Albumin response rate after 1,2,3&6 months	98
Fig. (17)	Changes in PC in the total studied population	100
Fig. (18)	PC response rate after 1,2,3&6 months	101
Fig. (19)	Changes in AST in the total studied population	103
Fig. (20)	AST response rate after 1,2,3&6 months	104
Fig. (21)	Correlation of changes in HCV titre with changes in AST in 3 rd month	106
Fig. (22)	Correlation of changes in HCV titre with changes in AST in 6 th month	107
Fig. (23)	Change in ALT in the total studied population	108
Fig. (24)	ALT response rate after 1,2,3 months and six months	109
Fig. (25)	Correlation of changes in HCV titre with changes in ALT in 2 nd month	111
Fig. (26)	Progress of Child-Pugh score in both studied groups after 1, 2, 3,	114

	and 6 months of transplant	
Fig. (27)	Child grade response rate after 1,2,3 months and six months	115
Fig. (28)	Progress of performance score in the studied population before transplant, after 1, 2, 3 and 6 months	118
Fig. (29)	PS response rate after 1,2, 3 and 6 months	119
Fig. (30)	Progress of the degree of ascites in the studied population	122
Fig. (31)	Response rate in the degree of ascites after 1, 2, 3 & 6 months	124
Fig. (32)	Change in the occuring of hepatic encephalopathy after 1, 2, 3 & 6 months	127
Fig. (33)	Change in the occuring of haematemesis after 1, 2, 3 & 6 months	131

List of abbreviations

2-AAF	2-acetylaminofluorene
ABMI	Autologous bone marrow cell infusion
BM	Bone marrow
BMSCs	Bone marrow stem cells
BMT	Bone marrow transplantation
CK	Cytokeratin
CLD	Chronic liver diseases
CPT	Child Pugh Turcotte classification
ECM	Extracellular matrix
EB	Embryonal body
EPC	Endothelial progenitor cell
ERK-1 & 2	Extracellular signal-regulated kinases 1 and 2
ES cells	Embryonic stem cells
FAH	Fumaryl acetoacetate hydrolase
FAK	Focal adhesion kinase
HCV	Hepatitis C virus
HCC	Hepatocellular carcinoma
HE	Hepatic encephalopathy
HSCs	Haematopoietic stem cells
IL	Interleukin
INR	International normalized ratio
MAPC	Multipotent adult progenitor cells
MELD	Model for end-stage liver disease
MSCs	Mesenchymal stem cells
NTCB	2-nitro 4-trifluoro-methylbenzoyl-1, 3 cyclohexanedion
OLT	Orthotopic liver transplantation
PHx	Partial hepatectomy
PKC	Protein kinase C
Pyk-2	Proline-rich tyrosine kinase 2
SDF-1	Stromal derived growth factor
TSSC	Tissue-specific stem cells
UCB	Umbilical cord blood
VCAM-1	Vascular endothelial cell adhesion molecule
VLA	Very late antigen

INTRODUCTION

Hepatitis C virus (HCV) infection is gaining increasing attention as a global health crisis. Egypt reports the highest prevalence of HCV worldwide, ranging from 6% to more than 40% among regions and demographic groups. **(Lehman and Wilson.,2009)**

Only 15-20% of people infected with HCV have an acute viral hepatitis syndrome, but the majority develop chronic hepatitis that is usually asymptomatic and undetected for many years. Over a course of 20-40 years, 20% of those with HCV-caused chronic hepatitis progress to cirrhosis, and a proportion of these (possibly 2-3% per year) die as a result of complications of cirrhosis or hepatocellular carcinoma. **(Strickland et al.,2002)**

End stage liver disease (ESLD) is a health problem worldwide. Liver transplantation is currently the only effective therapy, but its many drawbacks include a shortage of donors, operative damage, risk of rejection and in some cases recidivism of the pre-transplant disease. These factors account for the recent growing interest in regenerative medicine **(Lorenzini et al.,2008)**.

New therapies have been actively searched for over several decades, primarily in the form of hepatocyte transplantation. Stem cells have recently shown promise in cell therapy because they have the capacity for self-renewal and multilineage differentiation, and are applicable to human diseases. Very recent reports of unexpected plasticity in adult bone

marrow have raised hopes of stem cell therapy offering exciting therapeutic possibilities for patients with chronic liver disease. Both rodent and human embryonic stem cells, bone marrow stem cells, , umbilical cord blood cells, fetal liver progenitor cells, adult liver progenitor cells, and mature hepatocytes have been reported to be capable of self-renewal, giving rise to daughter hepatocytes both in vivo and in vitro. These cells can repopulate livers in animal models of liver injury and appear to be able to improve liver function. **(Bae ;2008)**

Hematopoietic stem cells (HSCs) and mesenchymal stem cell (MSCs) are two main subtypes of bone marrow stem cells. The diseased liver may recruit migratory stem cells, particularly from the bone marrow, to generate hepatocyte-like cells either by transdifferentiation or cell fusion. Transplantation of BMSCs has therapeutic effects of restoration of liver mass and function, alleviation of fibrosis and correction of inherited liver diseases. BMSCs can be delivered via intraportal vein, systemic infusion, intraperitoneal, intrahepatic, intrasplenic. The optimal stem cells delivery should be easy to perform, less invasive and traumatic, minimum side effects, and with high cells survival rate.**(Xuyq and Liu ;2008)**

BMSC transplantation can significantly improve the liver function of patients with terminal liver disease with good safety and effectiveness. **(Pan et al.,2008)**

Bhupinder and Maria Velez (2004) indicated that there is no correlation between any of the clinical and laboratory parameters and HCV viral loads & the severity of liver disease is independent of serum levels of hepatitis C virus. The precise mechanism by which hepatitis C virus damages the liver remains poorly understood. Until recently, a direct cytopathic effect of the virus was considered as the primary form of

liver injury caused by the virus. It has been suggested that the degree of liver damage is the result of a complicated interaction between virus and immune response of the host . Immune mediated liver damage is believed to be initiated by HCV-specific T cells and is enhanced by HCV-induced HLA-A, B and C and intracellular adhesion molecules . The results of **Bhupinder and Maria Velez (2004)** are important since they argue against a direct cytopathic effect of HCV and support the hypothesis that the pathogenesis of HCV-related liver damage is immune-mediated.

HCV RNA levels do not appear to differ significantly among patients with chronic active hepatitis with or without compensated cirrhosis. In contrast, HCV RNA levels seem to be significantly lower in patients with end-stage HCV-related liver cirrhosis. In these patients, high levels of replication are restored after liver transplantation, suggesting that low pretransplant viral loads are not due to the intrinsic characteristics of the infective viral strains, but rather to the severity of liver disease.(**Duvoux et al.,1999**)

The increase in HCV RNA concentration following the initial postanhepatic decline were dramatic, ranging from 1.4 log₁₀ to 6.0 log₁₀, and reached a steady state higher than the pretransplantation level in patients . These new steady states were between 1.4 and 450 times higher than the mean preanhepatic serum HCV RNA levels. Interestingly, patients with higher baseline viral loads reached the posttransplantation steady state faster. (**Kimberly et al.,2006**)

After stem cell transplantation, on comparing the biochemical parameters of patients grouped according to the etiology of their liver disease into viral and non-viral causes, it was observed that the mean serum albumin, bilirubin and INR levels were improving for the initial 3 months in post-viral cirrhotic patients group then started to decline once again, while in the non-viral group, this improvement continued

throughout the follow-up period. This difference was statistically significant as regards the serum albumin level, however it did not reach a statistical significance in the case of serum bilirubin and INR. This could be attributed to reactivation of the virus affecting the transplanted cells **(Azab.,2008)**

Piscaglia et al (2007) have shown that G-CSF facilitates hepatic regeneration by increasing the migration of BM-derived progenitors to the liver, as well as enhancing the endogenous oval cell reaction.

G-CSF has proven itself to be an anti-inflammatory immunomodulator. Animal, volunteer, and patient studies have all shown that G-CSF reduces inflammatory activity by inhibiting the production or activity of the main inflammatory mediators interleukin-1, tumor necrosis factor-alpha, and interferon gamma.**(Hartung ;1998).**

AIM OF OUR STUDY:

Main objective: as outcome of stem cell therapy in post HCV end stage liver cirrhosis is variable and patients receiving stem cell therapy for non viral end stage liver cirrhosis had better outcome, we aimed to determine the relation between HCV viral load and the outcome of stem cell therapy in patients with post HCV liver cirrhosis.

Sub-objective: Estimation of HCV viral load after taking G-CSF given to post viral cirrhotic patient before stem cell therapy as it may help to decrease viral load which in turn may improve outcome of stem cell therapy.